Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective
Authors:
- 21 June 2021
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (12) , 3039-3042
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from a hematopoietic stem cell, with plasmacytoid dendritic cells as their normal counterpart. BPDCN is enlisted as...Keywords
This publication has 14 references indexed in Scilit:
- More on Blastic Plasmacytoid Dendritic-Cell NeoplasmsNew England Journal of Medicine, 2019
- Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell NeoplasmNew England Journal of Medicine, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignanciesLeukemia & Lymphoma, 2017
- Treatment of blastic plasmacytoid dendritic cell neoplasmHematology-American Society Hematology Education Program, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaBlood, 2016
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10‐Color flow cytometry diagnosis and HyperCVAD therapyAmerican Journal of Hematology, 2015
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Novel markers of normal and neoplastic human plasmacytoid dendritic cellsBlood, 2008